Welcome to our dedicated page for Elanco Animal Health Incorporated news (Ticker: ELAN), a resource for investors and traders seeking the latest updates and insights on Elanco Animal Health Incorporated stock.
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health, committed to innovating and delivering products and services to improve the health and wellness of both farm animals and pets. Established with nearly 70 years of heritage, Elanco operates in over 90 countries with a diverse portfolio of approximately 200 brands. Their core mission is encapsulated in their vision: 'Food and Companionship Enriching Life,' which they pursue through three primary avenues:
- Enhancing food security by improving the health and productivity of farm animals, thereby contributing to a safer, more affordable, and abundant food supply.
- Helping pets live longer, healthier lives through advanced veterinary products.
- Improving food safety standards globally.
Elanco’s dedication to animal health is reflected in their continuous innovation and quality systems, driven by a shared vision of enhancing life for animals and humans alike. This commitment is evident in their recent achievements and ongoing projects. For instance, Elanco's collaboration with Agtech company, Cattler, aims to provide data-driven solutions to cattle farmers, enhancing operational efficiency and productivity through services like Benchmark™ and Experior™.
Elanco's financial health is strong, with the company reporting consistent revenue growth and strategic investments aimed at future expansion. In their recent financial results, Elanco posted a 5% growth in the fourth quarter and strengthened their commercial infrastructure to support ongoing and future growth. They also announced the divestiture of their aqua business to streamline operations and focus on core areas, which is expected to reduce their debt leverage significantly by year-end.
Environmental sustainability is another critical focus for Elanco. Their recent partnership with Athian to create a livestock carbon insetting marketplace is a significant step towards reducing greenhouse gas emissions in the dairy and beef industries. Products like Bovaer®, which significantly reduce methane emissions from cattle, exemplify Elanco's commitment to sustainable farming practices.
Overall, Elanco continues to be at the forefront of animal health innovation, with substantial investments in R&D, strategic partnerships, and a clear commitment to sustainability and community health.
Elanco Animal Health has appointed Marcela A. Kirberger as the new general counsel and corporate secretary, effective June 22. Kirberger brings over 20 years of corporate legal experience, previously serving at Roche Diagnostics and other major firms. Her role will encompass all of Elanco’s legal functions. The company's CEO, Jeff Simmons, highlighted her extensive background in regulated and pharma sectors as a valuable asset. Kirberger is also an advocate for Indiana's life sciences industry and aims to make a positive impact on animal health.
Kindred Biosciences (NASDAQ: KIN) announced positive results from a pivotal study of KIND-030 for treating canine parvovirus. The trial showed a 100% survival rate in dogs treated with KIND-030 compared to 43% in the placebo group. This monoclonal antibody targets canine parvovirus, offering a single injection treatment that eliminates the need for costly hospitalization. The results indicate potential for both treatment and prevention of the disease, with submissions for regulatory approval expected soon. Parvovirus has a mortality rate up to 91% if untreated, making this a critical advancement.
Elanco Animal Health Incorporated (NYSE: ELAN) has announced its participation in two upcoming investor conferences in June. Jeff Simmons, the president and CEO, will hold a fireside chat at the Stifel 2021 Virtual Jaws & Paws Conference on June 3 at 2:30 p.m. ET, lasting approximately 25 minutes. He will also present at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10 at 9:40 a.m. ET for about 40 minutes. Both conferences will be virtual, with live webcasts accessible on Elanco's investor website.
Elanco Animal Health has launched ZoaShield™ in the U.S., a solution for poultry producers to manage coccidiosis effectively. This new product features a proven active ingredient, zoalene, which is vital for maintaining optimal bird health, especially in No Antibiotics Ever (NAE) flocks. Elanco emphasizes that ZoaShield offers producers flexibility to suit various operational needs and seasons. Additionally, the company provides consultative support from experienced field experts, enhancing operational efficiency for poultry producers.
Elanco Animal Health reported strong Q1 2021 results, achieving revenue of $1,242 million, a significant rise from previous guidance of $1,150 - $1,170 million. The addition of Bayer Animal Health contributed $559 million to revenue. Adjusted EPS was $0.37, exceeding expectations. Pet Health revenue surged 213%, while global Seresto sales declined by 9%. Operating expenses were lower than anticipated, enabling Elanco to raise its 2021 guidance for revenue and adjusted EBITDA. The company expects eight product launches to drive future revenue growth.
Elanco Animal Health has launched Credelio Cat, the first oral flea and tick control product for cats, approved by the FDA. This chewable treatment starts killing fleas within 6 hours and provides protection against black-legged ticks for a month. Designed for cats 8 weeks and older, Credelio Cat is palatable and has a high success rate in administration, with 99.5% of owners successfully giving it to their cats. The product joins Elanco's extensive pet health portfolio, addressing a significant market need for effective oral parasite prevention in cats.
On April 28, 2021, Kindred Biosciences (NASDAQ: KIN) announced that the USDA has accepted the efficacy data for its monoclonal antibody, KIND-030, aimed at preventing canine parvovirus (CPV) infection. The pivotal study showed that 0% of treated dogs developed CPV, while the placebo group had a 100% infection rate. This acceptance is a significant milestone, progressing KindredBio's drug development for pets. The company expects to complete the efficacy study for treating established CPV by mid-2021.
Elanco has partnered with Ducks Unlimited to enhance environmental sustainability in beef cattle production across North America. From 2021 to 2023, Elanco will invest $50,000 annually to purchase grass seed for reseeding projects in western Kansas, aiming to restore 1,000 acres through the SAFE initiative. This collaboration aligns with Elanco’s sustainability framework, Healthy Purpose. Additionally, the announcement coincides with the launch of Experior™, a product approved by the FDA to reduce ammonia emissions from cattle waste, underscoring Elanco's commitment to sustainable agriculture.
Elanco Animal Health (NYSE: ELAN) will announce its first quarter 2021 financial results on May 7, 2021. A conference call will follow at 8:00 a.m. ET, accessible to investors, media, and the public via a webcast on Elanco’s website. This event aims to provide detailed insights into the company's performance during the quarter. Elanco is focused on innovating products to improve animal health, with nearly 70 years of experience in the industry.
Elanco Animal Health (NYSE: ELAN) responded to a U.S. House subcommittee request regarding misleading media claims about Seresto collars. The company reaffirms the safety and efficacy of Seresto, stating no recall is warranted. Over 25 million collars have been sold since 2012 with an adverse event rate below 0.3%, primarily non-serious. Elanco collaborates with the subcommittee and emphasizes the lack of scientific basis for a recall. The company underscores its commitment to product safety and continuous monitoring of health data.
FAQ
What is the current stock price of Elanco Animal Health Incorporated (ELAN)?
What is the market cap of Elanco Animal Health Incorporated (ELAN)?
What is Elanco Animal Health's core mission?
In how many countries does Elanco operate?
What recent collaborations has Elanco engaged in?
What is the significance of Elanco's partnership with Athian?
What are some of Elanco's notable products?
How is Elanco addressing sustainability in animal farming?
What financial goals has Elanco set for 2024?
How does Elanco contribute to food safety?
What is Elanco's approach to innovation?